Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects

Clinical Pharmacology and Therapeutics

Volumn 75, Issue 3, 2004, Pages 157-162

  Park, Ji Young ^a   Kim, Kyoung Ah ^b   Kang, Mun Ho ^b   Kim, Su Lyun ^b   Shin, Jae Gook ^b  

^a Gachon University College of Medicine   (South Korea)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; PLACEBO; RIFAMPICIN; ROSIGLITAZONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SCREENING; ETHNIC GROUP; HEMOCONCENTRATION; HUMAN; HUMAN EXPERIMENT; MALE; MEASUREMENT; METHODOLOGY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CROSS-OVER STUDIES; DRUG INTERACTIONS; HUMANS; MALE; METABOLIC CLEARANCE RATE; RIFAMPIN; STATISTICS, NONPARAMETRIC; THIAZOLIDINEDIONES;

EID: 1542286164     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2003.10.003     Document Type: Article

References (38)

1. Malinowski J.M., Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus a critical review. Clin Ther. 22:2000;1151-1168.
2. Balfour J.A., Plosker G.L. Rosiglitazone. Drugs. 57:1999;921-930.
3. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 270:1995;12953-12956.
4. Cox P.J., Ryan D.A., Hollis F.J., Harris A.M., Miller A.K., Vousden M., et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos. 28:2000;772-780.
5. Baldwin S.J., Clarke S.E., Chenery R.J. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol. 48:1999;424-432.
6. Combalbert J., Fabre I., Fabre G., Dalet I., Derancourt J., Cano J.P., et al. Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos. 17:1989;197-207.
7. Kolars J.C., Schmiedlin-Ren P., Schuetz J.D., Fang C., Watkins P.B. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest. 90:1992;1871-1878.
8. Strayhorn V.A., Baciewicz A.M., Self T.H. Update on rifampin drug interactions III. Arch Intern Med. 157:1997;2453-2458.
9. Finch C.K., Chrisman C.R., Baciewicz A.M., Self T.H. Rifampin and rifabutin drug interactions an update. Arch Intern Med. 162:2002;985-992.
10. Madan A., Graham R.A., Carroll K.M., Mudra D.R., Burton L.A., Krueger L.A., et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos. 31:2003;421-431.
11. Gerbal-Chaloin S., Pascussi J.M., Pichard-Garcia L., Daujat M., Waechter F., Fabre J.M., et al. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 29:2001;242-251.
12. Muxlow A.M., Fowles S., Russell P. Automated high-performance liquid chromatography method for the determination of rosiglitazone in human plasma. J Chromatogr B Biomed Sci Appl. 752:2001;77-84.
13. Otto C., Lehrke M., Goke B. Novel insulin sensitizer pharmacogenomic aspects. Pharmacogenomics. 3:2002;99-116.
14. Watanabe I., Tomita A., Shimizu M., Sugawara M., Yasumo H., Koishi R., et al. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 73:2003;435-455.
15. Miller A.K., DiCicco R.A., Freed M.I. The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers. Clin Ther. 24:2002;1062-1071.
16. Miller A.K., Inglis A.M., Culkin K.T., Jorkasky D.K., Freed M.I. The effect of acarbose on the pharmacokinetics of rosiglitazone. Eur J Clin Pharmacol. 57:2001;105-109.
17. Rao M.N., Mullangi R., Katneni K., Ravikanth B., Babu A.P., Rani U.P., et al. Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. J Clin Pharmacol. 42:2002;670-675.
18. Harris R.Z., Inglis A.M., Miller A.K., Thompson K.A., Finnerty D., Patterson S., et al. Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics. J Clin Pharmacol. 39:1999;1189-1194.
19. Di Cicco R.A., Miller A.K., Patterson S., Freed M.I. Rosiglitazone does not affect the steady-state pharmacokinetics of digoxin. J Clin Pharmacol. 40:2000;1516-1521.
20. Inglis A.M., Miller A.K., Culkin K.T., Finnerty D., Patterson S.D., Jorkasky D.K., et al. Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers. J Clin Pharmacol. 41:2001;683-690.
21. Di Cicco R.A., Allen A., Carr A., Fowles S., Jorkasky D.K., Freed M.I. Rosiglitazone does not alter the pharmacokinetics of metformin. J Clin Pharmacol. 40:2000;1280-1285.
22. Obach R.S., Zhang Q.Y., Dunbar D., Kaminsky L.S. Metabolic characterization of the major human small intestinal cytochrome P450s. Drug Metab Dispos. 29:2001;347-352.
23. Hansen J.M., Christensen L.K. Drug interactions with oral sulphonylurea hypoglycaemic drugs. Drugs. 13:1977;24-34.
24. Niemi M., Backman J.T., Neuvonen M., Neuvonen P.J., Kivisto K.T. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther. 69:2001;400-406.
25. Niemi M., Backman J.T., Neuvonen M., Neuvonen P.J., Kivisto K.T. Rifampin decreases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther. 68:2000;495-500.
26. Park J.Y., Kim K.A., Park P.W., Park C.W., Shin J.G. Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. Clin Pharmacol Ther. 74:2003;334-340.
27. Niemi M., Backman J.T., Granfors M., Laitila J., Neuvonen M., Neuvonen P.J. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia. 46:2003;1319-1323.
28. Sonnichsen D.S., Liu Q., Schuetz E.G., Schuetz J.D., Pappo A., Relling M.V. Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther. 275:1995;566-575.
29. Nadin L., Murray M. Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes. Biochem Pharmacol. 58:1999;1201-1208.
30. Ohyama K., Nakajima M., Nakamura S., Shimada N., Yamazaki H., Yokoi T. A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation an approach to predict the contribution with relative activity factor. Drug Metab Dispos. 28:2000;1303-1310.
31. Li X.Q., Bjorkman A., Andersson T.B., Ridderstrom M., Masimirembwa C.M. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8 a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther. 300:2002;399-407.
32. Klose T.S., Blaisdell J.A., Goldstein J.A. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol. 13:1999;289-295.
33. Avandia (GlaxoSmithKline). In: Physician's desk reference electronic library [CD-ROM]. Vol. 2003.1. Montvale (NJ): Thomson Medical Economics; 2003
34. Wagstaff A.J., Goa K.L. Rosiglitazone a review of its use in the management of type 2 diabetes mellitus. Drugs. 62:2002;1805-1837.
35. Rosiglitazone Clinical Trials Study Group, Phillips L.S., Grunberger G., Miller E., Patwardhan R., Rappaport E.B., Salzman A. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care. 24:2001;308-315.
36. Jasmer R.M., Nahid P., Hopewell P.C. Clinical practice. Latent tuberculosis infection. N Engl J Med. 347:2002;1860-1866.
37. Chapelsky M.C., Thompson-Culkin K., Miller A.K., Sack M., Blum R., Freed M.I. Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. J Clin Pharmacol. 43:2003;252-259.
38. Patel B.R., Diringer K., Conrad J., Miller A., Rappaport E., Boyle D. Population pharmacokinetics of rosiglitazone (R) in phase III clinical trials. [abstract] Clin Pharmacol Ther. 67:2000;123.